国元国际发布研报称，给予石药集团（01093）"买入"评级，目标价10.11港元，公司积极布局创新药， 研发投入加大，出海成果突出，公司持续高强度投入研发，已构建国际化管线与领先平台，出海成果显 著。尽管短期内成药业务受集采影响承压，但单季度业绩已呈现企稳回升态势，且多款核心创新药临近 关键节点，授权收入成为新增长点，为中长期增长奠定坚实基础。 国元国际主要观点如下： 新药研发投入加大，研发平台优势明显 公司已建成一支逾2000人的国际化研发团队，聚焦于抗肿瘤、精神神经、心血管等治疗领域，拥有8大 研发平台。研发费用41.85亿元，同比增长7.9%，占成药收入27.1%，显示公司持续高强度投入创新，有 近90个产品在临床试验的不同阶段，14款产品已递交上市申请，30余款处于注册临床阶段，为未来收入 结构转型奠定基础，公司计划在未来5年内申报近50款新产品/新适应症上市。 新药研发快速推进，出海成果突出 创新管线加速兑现，授权费收入15.40亿元贡献新增长极，海外授权协议累计潜在里程碑付款超150亿美 元，国际化战略成效初显。SYS6091（HER2ADC）、SYS6010（EGFRADC）、安尼妥单抗（HER ...

Group 1 - The overall industry sentiment shows an upward trend in sectors such as steel, electric equipment, electronics, food and beverage, environmental protection, and retail, while sectors like oil and petrochemicals, machinery, light manufacturing, home appliances, automotive, banking, real estate, and public utilities are experiencing a downward trend [3][22] - As of August 10, 2025, notable industry data includes: automotive semi-steel tire operating rate at 74.35%, down 0.1% month-on-month; machinery equipment price index at 125.17 points, down 0.11% month-on-month; electric equipment Topcon component price at 0.7 yuan/watt, up 4.2% month-on-month; transportation with Suzhou subway passenger volume at 2.156 million, up 27.57% month-on-month; light manufacturing white cardboard price at 4010 yuan/ton, down 2.43% month-on-month [3][23][24] Group 2 - Insurance capital is increasingly allocating to equity, with banks and high-dividend sectors being core beneficiaries. By the end of Q1 2025, life and property insurance companies had invested a total of 2.82 trillion yuan in the stock market, a year-on-year increase of 44.5% [5] - The potential for insurance capital to increase its allocation to bank stocks remains significant, with estimated incremental funds of 140.4 billion yuan and 73.7 billion yuan for bank stocks in 2025, assuming 25% of new premium income is directed to the A-share market [5] Group 3 - The report on Shiyao Group indicates a revenue of 7.015 billion yuan in Q1 2025, a year-on-year decrease of 21.9%, with a net profit of 1.495 billion yuan, down 8.3%. The decrease in revenue is primarily due to the impact of price adjustments and centralized procurement policies [8][28] - The core pipeline SYS6010 (EGFRADC) shows strong potential for authorization, having started its first phase III clinical trial in March 2025, targeting patients with EGFR mutation non-small cell lung cancer [8][28] Group 4 - Shenzhen Airport's operational data shows a significant recovery, with 221,000 aircraft movements in the first half of 2025, a year-on-year increase of 7.2%, and a passenger throughput of 32.57 million, up 10.9% year-on-year [19][30] - The airport's non-aeronautical business is diversifying, with advertising revenue expected to increase as passenger traffic grows, and the new cargo station is anticipated to boost international cargo volume [19][31] Group 5 - Beiding Co. reported a revenue of 430 million yuan in the first half of 2025, a year-on-year increase of 34%, with a net profit of 56 million yuan, up 75% year-on-year. The company benefited significantly from domestic subsidies and the "old-for-new" replacement policy [10][36] - The company's gross margin improved to 49.7% in the first half of 2025, driven by high-margin products, with a notable increase in sales from new product lines [10][36]